Acute Leukemia, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
Martin S. Tallman
Topics for this issue will include: CLL: A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What ...view more
Topics for this issue will include: CLL: A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?
Topics for this issue will include: CLL: A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?
Author Information
By Martin S. Tallman, MD, Chief, Leukemia Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
https://www.us.elsevierhealth.com/acute-leukemia-an-issue-of-hematologyoncology-clinics-of-north-america-9781455711970.html6708Acute Leukemia, An Issue of Hematology/Oncology Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455711970_7.jpg69.2998.99USDInStock/Medicine/Hematology/Clinics/Clinics1374388725525504113841826925145120Topics for this issue will include: CLL: A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy? Topics for this issue will include: CLL: A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?00add-to-cart97814557119702011 and earlierProfessionalBy Martin S. Tallman, MD20111Book152w x 229h (6.00" x 9.00")Saunders0Dec 14, 2011IN STOCK - This may take up to 5 business days to shipBy <STRONG>Martin S. Tallman</STRONG>, MD, Chief, Leukemia Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NYClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
